1. 2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis. Issue 3 (September 2015) Authors: Kristeleit, R.; Swisher, E.; Oza, A.; Coleman, R.L.; Scott, C.; Konecny, G.; Tinker, A.; O'Malley, D.M.; Brenton, J.; Bell-McGuinn, K.; Oaknin, A.; Leary, A.; Lin, K.K.; Raponi, M.; Giordano, H.; Maloney, L.; Goble, S.; Yelensky, R.; McNeish, I. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. (September 2015) Authors: Shapira-Frommer, R.; Oza, A.; Domchek, S.M.; Balmana, J.; Patel, M.R.; Chen, L.M.; Drew, Y.; Burris, H.A.; Korach, J.; Flynn, M.; Bowering, V.L.; Morgan, M.A.; Watkins, S.P.; Simpson, D.; Goble, S.; Maloney, L.; Kristeleit, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Issue 16 (November 2015) Authors: Suder, A.; Ang, J.E.; Kyle, F.; Harris, D.; Rudman, S.; Kristeleit, R.; Solca, F.; Uttenreuther-Fischer, M.; Pemberton, K.; Pelling, K.; Schnell, D.; de Bono, J.; Spicer, J. Journal: European journal of cancer Issue: Volume 51:Issue 16(2015:Nov.) Page Start: 2275 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗